{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:22:40Z","timestamp":1777929760404,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,21]],"date-time":"2009-04-21T00:00:00Z","timestamp":1240272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,21]],"date-time":"2009-04-21T00:00:00Z","timestamp":1240272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Maligne Non-Hodgkin-Lymphome (NHL) von hohem Malignit\u00e4tsgrad der Kieler Klassifikation wurden vom Juli 1978 bis August 1980 mit einer sequentiellen Chemotherapie behandelt. Nach der Kombination von Cyclophosphamid, Vincristin, Bleomycin und Prednison (Phase A) wurde die Kombination von Adriamycin, Cytosin Arabinosid, 6-Thioguanin und Prednison (Phase B) gegeben. Die Patienten erhielten 4 Zyklen beider Kombinationen ohne anschlie\u00dfende Erhaltungstherapie. 20 Patienten mit zentroblastischem, immunoblastischem oder lympho-blastischem NHL wurden in die Studie aufgenommen. Bei 95% (19 der 20 Patienten) der Patienten wurde eine komplette oder partielle Remission induziert. Die Rate kompletter Remissionen betrug 75% (15 der 20 Patienten). Die mediane Dauer der kompletten Remissionen betrug 28,7 Monate. Die statistische \u00dcberlebenswahrscheinlichkeit nach 2 Jahren betr\u00e4gt f\u00fcr die Patienten mit kompletter Remission 64,5%. Klinische prognostische Faktoren (Knochenmarkinfiltration, Befall extralymphatischer Organe, Lymphome mit einem Durchmesser von mehr als 10 cm) beeinflussen entscheidend die Remissionsinduktion und die \u00dcberlebenszeit. Alle Patienten mit g\u00fcnstiger Prognose \u00fcberleben in kompletter Remission 14-38 Monate nach Therapiebeginn. Die Kranken mit ung\u00fcnstiger Prognose haben eine Remissionsrate von 64% und eine mediane \u00dcberlebenszeit von 14,8 Monaten.<\/jats:p>","DOI":"10.1159\/000215007","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T10:40:22Z","timestamp":1240396822000},"page":"222-227","source":"Crossref","is-referenced-by-count":0,"title":["Sequentielle Chemotherapie maligner Non-Hodgkin-Lymphome (NHL) von hohem Malignit\u00e4tsgrad im Stadium III und IV"],"prefix":"10.1159","author":[{"given":"P.S.","family":"Mitrou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,21]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/215007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000215007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:53:01Z","timestamp":1777679581000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000215007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,21]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000215007","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,21]]}}}